Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas

Published:2018-06-14 Issue:24 Volume:24 Page:6483-6494
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Dankner Matthew,Lajoie Mathieu,Moldoveanu Dan,Nguyen Tan-Trieu,Savage Paul,Rajkumar Shivshankari,Huang Xiu,Lvova Maria,Protopopov Alexei,Vuzman Dana,Hogg David,Park Morag,Guiot Marie-Christine,Petrecca Kevin,Mihalcioiu Catalin,Watson Ian R.,Siegel Peter M.,Rose April A.N.

Funder

DOD

Melanoma Research Alliance

V Foundation

CIHR

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

2. CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers;2024-07-29

3. Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP;Journal of Pathology and Translational Medicine;2024-07-15

4. Characterization of BRAF^Thr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling;JCO Precision Oncology;2024-04

5. Molecular characterization of Chinese patients with small bowel adenocarcinoma;Clinical and Translational Oncology;2024-03-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP